Aptose Biosciences is a biotechnology business based in the US. Aptose Biosciences shares (APTO) are listed on the NASDAQ and all prices are listed in US Dollars. Aptose Biosciences employs 35 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.62 |
|---|---|
| 52-week range | $0.59 - $5.10 |
| 50-day moving average | $0.92 |
| 200-day moving average | $1.79 |
| Wall St. target price | $11.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-6.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6194 from 2024-07-22
| 1 week (2024-07-17) | -6.86% |
|---|---|
| 1 month (2024-06-24) | -16.52% |
| 3 months (2024-04-24) | -49.23% |
| 6 months (2024-01-24) | -70.36% |
| 1 year (2023-07-24) | -85.46% |
|---|---|
| 2 years (2022-07-22) | -19.56% |
| 3 years (2021-07-23) | 2.76 |
| 5 years (2019-07-24) | 2.7 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -115.15% |
| Return on equity TTM | -361.05% |
| Profit margin | 0% |
| Book value | $0.01 |
| Market Capitalization | $12 million |
TTM: trailing 12 months
We're not expecting Aptose Biosciences to pay a dividend over the next 12 months.
Aptose Biosciences's shares were split on a 1:12 basis on 5 October 2014. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptose Biosciences shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Aptose Biosciences shares which in turn could have impacted Aptose Biosciences's share price.
Over the last 12 months, Aptose Biosciences's shares have ranged in value from as little as $0.59 up to $5.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptose Biosciences's is 1.474. This would suggest that Aptose Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aptose Biosciences Inc. , a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.